Tolerance, Pharmacokinetics / Pharmacodynamics (PK / PD) and Immunogenicity of Pegylated Uric Acid Oxidase for Injection in Healthy Adults and Hyperuricemia Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

54 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-08

Study Completion Date

2023-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomized, double-blind, placebo-controlled study of tolerance, pharmacokinetic / pharmacodynamics (PK / PD) and immunogenicity of single administration of PEG uric oxidase for injection in healthy adults and hyperuricemia volunteers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic Hyperuricemia

NCT05302388

Asymptomatic Hyperuricemia

COMPLETED PHASE1

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects

NCT03906006

Gout Hyperuricemia

COMPLETED PHASE1

Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout

NCT00325195

Gout

COMPLETED PHASE3

Safety and Efficacy Study of Intravenous Uricase-PEG 20

NCT01021241

Gout Hyperuricemia

UNKNOWN PHASE1

Safety and Efficacy Study of Intramuscular Uricase-PEG 20

NCT01038947

Gout Hyperuricemia

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperuricemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PEGylated Urate Oxidase for Injection

PEGylated Urate Oxidase for Injection，specification:5mg，Single dose ascending.Healthy subjects were divided into three dose groups (0.5mg, 1mg, 2mg), and hyperuricemia patients were divided into four dose groups (2mg, 4mg, 8mg, 12 mg), with increasing dose design.Each group will receive the experimental drug in 6 subjects.

Group Type EXPERIMENTAL

Polyglycol lated urate oxidase for injection

Intervention Type DRUG

Single dose escalation

Placebo

Placebo , specification: 5mg,Single dose. Groups received the placebo in 2 patients per group.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Polyglycol lated urate oxidase for injection

Single dose escalation

Intervention Type DRUG

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy volunteers:

* Subjects understand well trial purpose, nature, content, process and possible adverse reactions, and voluntarily sign an informed consent form.
* Serum uric acid level\<360 µ mol / L twice on different days.
* Healthy male or female aged between 18 and 60 years old (including the critical value).
* The body mass index is in the range of 18-30kg/m2 (including the critical value). The weight of male is not less than 50 kg, and that of female is not less than 45 kg (including the critical value).
* Subjects who had not any medical history of cardiovascular, digestive, respiratory, nervous, haemal diseases or hepatic/renal impairment.The following examination show that the indicators are normal or abnormal without clinical significance. The examination including: physical examination, 12-lead ECG, vital sign measurements and laboratory safety tests .
* The subjects have no family planning within 6 months and could select contraceptive method. They have no sperm and egg donation program.
* Before the study, all subjects have been informed of the study's purpose, protocal, benefits, and risks, and signed the informed consent voluntarily.
* The blood pregnancy test of female subjects was negative, the menstrual cycle was regular, and the menstrual bleeding period was 3 \~ 7 days.

Patients with hyperuricemia:

* Patients with hyperuricemia ,male or female aged between 18 and 60 years old (including the critical value).
* Stop uric acid lowering treatment for at least 7 days, and 480≤UA≤540µmol/L twice on different days within 7 days.
* The body mass index is in the range of 18-30kg/m2 (including the critical value). The weight of male is not less than 50 kg, and that of female is not less than 45 kg (including the critical value).
* Before the study, all subjects have been informed of the study's purpose, protocal, benefits, and risks, and signed the informed consent voluntarily.
* The blood pregnancy test of female subjects was negative, the menstrual cycle was regular, and the menstrual bleeding period was 3 \~ 7 days.

Exclusion Criteria

* Healthy volunteers:

* A history of drug allergy, or allergic allergic disease, or known to be allergic to the test drug or its excipients or the same type of drug;
* Hepatitis (including hepatitis B and C), positive screening results for AIDS or syphilis;
* Any history of acute or chronic illness that might affect drug absorption, and/or metabolism;
* Any history of drug abuse in the past 12 months prior to screening;
* Any history of alcohol abuse 3 months prior to screening or moderate drinkers (drink more 2 units per day or 14 units per week);
* Smoking more than 5 cigarettes per day during the 3 months prior to screening;
* Blood donation, massive blood loss (#400mL) or enrolled in other clinical trials 3 months prior to screening;
* Any use of other prescription drugs (including contraceptive)#over-the counter drugs, Chinese herbal medicine, health care products and 14 days prior to medication for this study;
* Any history of postural hypotension, syncope, or amaurosis;
* 6-glucose phosphate dehydrogenase (G6PD) deficiency;
* Lactating or pregnant women

Patients with hyperuricemia:

* Using uric acid lowering drugs and unwilling to stop existing drugs.
* Ultrasonic examination of the metatarsal-toe joint suggested the presence of tophi.
* Serum CA72-4 level ≥7.5U / mL.
* History of organic heart disease (symptomatic cardiac insufficiency with grade II-IV).
* Patients with refractory hypertension.
* Patients with malignant tumors (treatment or not).
* Patients with organ transplantation treated with immunosuppressants.
* Any history of drug abuse in the past 12 months prior to screening;
* Any history of alcohol abuse 3 months prior to screening or moderate drinkers (drink more 2 units per day or 14 units per week).
* Smoking more than 5 cigarettes per day during the 3 months prior to screening.
* A history of drug allergy, or allergic allergic disease, or known to be allergic to the test drug or its excipients or the same type of drug.
* Any history of acute or chronic illness that might affect drug absorption, and/or metabolism.
* 6-glucose phosphate dehydrogenase (G6PD) deficiency.
* Once treated with urate oxidase.
* Subjects had an uncorrected dehydration, acidosis, hypotension, renal insufficiency, or were using drugs with nephrotoxicity.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes